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Michiel Haeseker1,3,5*, Thomas Havenith2, Leo Stolk2, Cees Neef2, Cathrien Bruggeman1,3 and Annelies Verbon4Abstract
Background: The pharmacodynamic (PD) efficacy target of amoxicillin is 40% time above the minimal inhibition
concentration (40%T > MIC). Recent studies of other antibiotics have shown that PD-efficacy targets are not always
reached. The aim of this study was to evaluate the percentage of hospitalised patients, using amoxicillin/clavulanic
acid intravenously (iv), that reach the pharmacodynamic efficacy target 40%T >MIC. Additionally, the association of
demographic anthropomorphic and clinical parameters with the pharmacokinetics and pharmacodynamics of
amoxicillin were determined.
Methods: In serum of 57 hospitalised patients amoxicillin concentrations were measured using high performance
liquid chromatography. Patients were older than 18 years and most patients had an abdominal infection. The
standard amoxicillin/clavulanic acid dose was 4 times a day 1000/200 mg iv. Pharmacokinetic parameters were
calculated with maximum a posteriori Bayesian estimation (MW\Pharm 3.60). A one-compartment open model was
used. Individual dosing simulations were performed with MW\Pharm.
Results: In our study population, the mean (±SD) age was 67 (±16) years and the mean clearance corrected for
bodyweight was 0.17 (±0.07) L/h/kg. Only, 65% of the patients reached the proposed amoxicillin 40%T > MIC with
amoxicillin/clavulanic acid for bacterial MICs of 8 mg/L. A computer simulated increase of the standard dose to 6
times daily, increased this percentage to 95%. In this small study group 40%T >MIC was not associated with clinical
or microbiological cure.
Conclusion: A substantial proportion of the hospitalised patients did not reach the 40%T > MIC with the standard
dose amoxicillin/clavulanic acid for a bacterial MIC of 8 mg/L. Therefore, we suggest increasing the standard dose
of amoxicillin/clavulanic acid to 6 times a day in patients with severe Enterobacteriaceae infections.
Trial registration: Trial registration number: NTR1725 16th march 2009.
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In vitro and animal studies have shown that β-lactam anti-
biotics for Gram-positive bacteria and Gram-negative bac-
teria are effective when the percentage time above the
minimal inhibition concentration (%T >MIC) of the un-
bound serum concentration is more than 35-40%. Max-
imal effects are reached with %T >MIC above 60-70%
[1-3]. Only sparse pharmacokinetic/pharmacodynamic
(PK/PD) data are estimated in human clinical studies.* Correspondence: m.haeseker@mumc.nl
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unless otherwise stated.Pharmacokinetic analysis of amoxicillin/clavulanic acid has
mostly been done in healthy individuals [4,5]. In human
clinical studies amoxicillin/clavulanic acid has been found
to cure Streptococcus pneumoniae and Haemophilus influ-
enza infections clinically and microbiologically when %T >
MIC was ≥40% [1]. To our knowledge, there are no human
pharmacodynamic efficacy studies for Enterobacteriaceae.
Amoxicillin/clavulanic acid is a commonly used broad
spectrum antibiotic. Clavulanic acid extends the spectrum
of amoxicillin to β-lactamase producing strains, such as E.
coli, K. pneumoniae, H. influenzae and S. aureus. Clavula-
nic acid has very little intrinsic antibacterial effect. Clavu-
lanic acid irreversibly inhibits β-lactamase, protecting
amoxicillin [6]. Therefore, amoxicillin is measured foral Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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of Enterobacteriaceae have changed over time, and recent
studies have shown that efficacy targets of other antibi-
otics, such as ciprofloxacin [7,8], ceftazidim [9] and genta-
micin [10] are not reached in a significant percentage of
patients. In the EUCAST rationale document the target
attainment rates for different doses of amoxicillin for
different MICs based on Monte Carlo simulations are
reported [11]. Amoxicillin blood levels have not been
measured in these simulations. The aim of this study was
to measure the amoxicillin serum concentrations in hospi-
talised patients using amoxicillin/clavulanic acid intra-
venously (iv) and to determine if the efficacy target of
40%T >MIC was reached. Additionally, we have investi-
gated the association of demographic anthropomorphic




Patients above 18 years of age treated with amoxicillin/cla-
vulanic acid iv and hospitalised at the Maastricht Univer-
sity Medical Centre (MUMC), a 715 bed university
hospital, were included from January 2010 until October
2010. Amoxicillin blood levels were measured in residual
samples drawn for routine assays. Patients with at least
two blood samples available were included and blood
samples taken during or within 0.5 hours after infusion
were excluded. Amoxicillin/clavulanic acid (Sandoz, Holz-
kirchen, Germany) was started at the discretion of the at-
tending physician, either empirically or as therapy for
bacteria susceptible to amoxicillin/clavulanic acid. The
standard dose of amoxicillin/clavulanic acid was 1000/
200 mg 4 times a day and 1000/200 mg 2 times a day was
prescribed when the creatinine clearance (CLcr) was 10–
50 ml/min. Amoxicillin/clavulanic acid 1000/200 mg/
100 mL infusion was infused in 30 minutes. Demographic
and clinical data, such as age, gender, weight, temperature,
co-medication, length of hospital stay, time of administra-
tion of amoxicillin/clavulanic acid and laboratory parame-
ters, such as, serum creatinine, C-reactive protein (CRP)
were retrieved from the electronic patient file (iSoft, the
Netherlands). Clinical outcome was defined by CRP nor-
malisation, number of admission days, and discharge from
the hospital, time to defeveresence and microbiological
cure. CLcr was calculated with the Cockcroft-Gault for-
mula using the lean body mass.
This study was registered at the Dutch Trial Register
(NTR 1725) [12] and was approved by the Medical
Ethical Committee of the Maastricht University Medical
Centre (MEC 08-4-063). All data in this study were ana-
lysed anonymously and amoxicillin blood levels were
measured in residual samples drawn for routine assays.
Therefore, no consent was required from the patient.This is in agreement with the Medical Research Involv-
ing Human Subjects Act, the code for proper use of
human tissue as formulated by the Dutch Federation of
Medical Scientific Societies and the policy of the Med-
ical Ethics Committee of the Maastricht University
Medical Centre.
HPLC analysis
A simple, fast and specific method for measuring amoxi-
cillin serum levels has been validated for linearity, preci-
sion, accuracy and stability, following the guidelines for
industry bioanalytical method validation recommended
by the Food and Drug Administration (FDA) [13]. In
short, serum samples were precipitated with perchloric
acid 3%. A reverse phase high pressure liquid chroma-
tography (RP-HPLC) method was used. The calibration
range was 10 to 200 mg/L. Six quality controls (8, 20,
40, 60, 80 and 160 mg/L) were tested. The intra- and
inter-assay variability was within 7.5%. The relationship
between plasma concentration and sd was fitted with a
polynomial of second order [14]. With this polynomial
the lower limit of quantification with a precision of 20%
has been calculated and was 0.8 mg/L [15]. All our mea-
sured concentrations were above 0.8 mg/L.
Pharmacokinetic analysis
Pharmacokinetic parameters of amoxicillin in individual
patients were calculated with maximum a posteriori
(MAP) Bayesian estimation program (computer program
MW/Pharm 3.60, Mediware, the Netherlands). A one-
compartment open pharmacokinetic model was used.
With MAP Bayesian estimation [16,17] all patient char-
acteristics and measured amoxicillin concentrations are
fitted on an existing population model [4,5]. With two
concentrations per patient individual pharmacokinetic
parameters can be adequately calculated with MAP
Bayesian estimation [17]. With these individual fitted
pharmacokinetic parameters, dosing simulations were
made to adjust the dose individually; this MAP Bayesian
estimation is standard procedure in laboratories which
provide therapeutic drug monitoring service. A po-
pulation kinetic model from our population was not
made. The free fraction of amoxicillin was fixed at
80%. The %T >MIC was determined with the formula
of Turnidge; %T >MIC = ln(Dose/VdxMIC) × T½/ln(2) ×
100/dosing interval [18]. Individual dosing simulations
were performed with MW-Pharm (3 times 1000–
2000 mg, 4 times 2000 mg, 5 times 1000–2000 mg,
6 times 1000–2000 mg).
Microbiological analysis
Identification of the causative bacterium (ID) and anti-
biotic susceptibility testing (AST) were performed with
the Becton Dickinson Phoenix™ Automated Microbiology
Table 1 Characteristics of 57 hospitalised patients
Mean (±SD) Median (range)
Age in years 67 (±16) 69 (23–93)
Weight in kg 78 (±20) 75 (43–153)
Number of blood levels 3 (±0.9) 2 (2–5)
Amoxicillin iv days 13 (±9) 10 (3–57)
Admission days 27 (±34) 19 (4–188)
Gender Number (percentage)
• Male 40 (70%)
• Female 17 (30%)
Infection Number (percentage)
• Abdominal infection 28 (49%)
• Wound infection 10 (17.5%)
• Pneumonia 6 (11%)
• Urinary tract infection 3 (5%)
• Other 10 (17.5%)
Amoxicillin combination Number (percentage)
• Monotherapy 44 (78%)
• Ciprofloxacin 4 (7%)
• Erythromycin 3 (5%)
• Gentamicin 3 (5%)
• Othera 3 (5%)
Co-medication Number (percentage)
• None 16 (28%)
• Cardiovascular 27 (47%)
• Diabetic mellitus 15 (26%)
• Immunosuppressive 3 (5%)
• Otherb 8 (14%)
aOther: rifampicin, cefuroxim and metronidazol.
bOther: haloperidol, levothyroxine, painkillers, anticoagulant.
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AST Combo panels UNMIC/ID53 and NMIC/ID75 for
Gram negative bacteria and the AST panel PMIC-58 for
Gram positive bacteria. In urine cultures the lowest
MIC detectable was 0.5 mg/L by the UNMIC/ID53 panel
(standard clinical care). MIC values were not determined
by the Becton Dickinson Phoenix™ for Streptococcal spp.
and Anaerobes. Susceptibility testing for Streptococcal spp.
and Anaerobes was done with the disc diffusion method.
Statistical analysis
Metric variables were tested for normality of distribution
by the Shapiro-Wilk test and presented as mean (±SD).
If not, median and ranges were also given. Categorical
variables are presented as frequencies and percentages.
Univariate analysis on the amoxicillin clearance cor-
rected for bodyweight (CLam/W) with categorical vari-
ables was either done by Student t-test or by one-way
ANOVA. Data analysis was done with SPSS-pc version




A total of 57 patients with a mean (±SD) of 3 (±0.9) blood
samples (median: 2, range 2–5 blood samples) were in-
cluded. The mean age was 67 (±16) years (median: 69,
range 23–93 years) and 70% were male (Table 1). About
half of the patients had an abdominal infection, 18% a
wound infection and 10% a pneumonia (Table 1).
Pharmacokinetic and pharmacodynamic analysis
The mean CLam/W was 0.17 (±0.07) L/h/kg (median:
0.16, range: 0.05-0.37 L/h/kg) and the mean volume of
distribution corrected for bodyweight (V/W) was 0.31
(±0.07) L/kg (median: 0.30, range: 0.19-0.50 L/kg). The
mean volume of distribution (V) was 24 (±5.6) L (median:
24, range: 14–36 L) and the mean elimination half-life
(t½) was 1.5 (±0.6) h (median: 1.3, range: 0.6-3.29 h) which
is in the same range as described in the EUCAST rationale
document [11]. The mean serum creatinine was 90 (±36)
μmol/L (median: 90, range: 49–210 μmol/L). Fifty-five
(96%) patients received the standard dose of amoxicillin/
clavulanic acid 4 times a day 1000/200 mg iv, 1 patient 3
times 1000/200 mg iv and 1 patient 2 times a day 1000/
200 mg iv, both because of renal insufficiency. Patients
above 70 years had lower CLam/W (P = 0.02), Table 2. A
significant correlation was found between CLam/W and
age (P < 0.001).
The measured concentrations of amoxicillin were plot-
ted against the sampling times in Figure 1. There was a
good linear correlation (R2 = 0.96) between the amoxicil-
lin actual measured concentration and estimated con-
centration with MAP Bayesian fitting (MW/Pharm 3.60,Mediware, the Netherlands), Figure 2. The amoxicillin
efficacy target (40%T >MIC) was reached in 100% of pa-
tients with a bacterial MIC ≤ 2 mg/L of Gram negative
bacteria, in 93% of patients with a MIC = 4 mg/L and in
65% of patients with a MIC = 8 mg/L (Figure 3). When
divided in age categories, arbitrarily set at 70 years; all
patients older than 70 years reached the 40%T >MIC
with a MIC of 4 mg/L and 87% of the patients younger
than 70 years. For a MIC of 8 mg/L, the 40%T >MIC
was reached in 81% of the patients older than 70 years
and in 52% of the patients younger than 70 years
(Figure 3).
Analysis of influence of co-variates on pharmacokinetic
and pharmacodynamic parameters
To determine which co-variates have an effect on the
pharmacokinetic parameters of amoxicillin, a univariate
analysis was done using a predetermined set of predic-
tors (Table 3). In the univariate analysis CLam/W was
Table 2 Mean (±SD) CLam/Wa, CLcrb, V/Wc and T½d for amoxicillin in patients using amoxicillin/clavulanic acid broken
down per age group
Age group in years N CLam/W in L/h/kg CLcr in mL/min V/W in L/kg T½ in h
<70 31 0.19 (±0.08) 82 (±25) 0.30 (±0.06) 1.26 (±0.44)
>70 26 0.14 (±0.06) 55 (±19) 0.32 (±0.08) 1.83 (±0.71)
P-value 0.02 <0.01 0.82 <0.01
aCLam/W: amoxicillin clearance corrected for bodyweight.
bCLcr: creatinine clearance.
cV/W: volume of distribution corrected for bodyweight.
dT½: amoxicillin half life.
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Linear correlations were found between CLam/W, cre-
atinine and age (R2 0.327), Vd (R2 0.370) and age (R2
0.227). In the univariate analysis age was not correlated
to creatinine (R 0.10, P = 0.467) and no linear correlation
(R2 0.01) was found.
Dosing simulations
To determine whether increasing the dose of amoxicillin/
clavulanic acid would lead to sufficiently high %T >MIC,
the %T >MIC was calculated for all patients with increas-
ing doses with the Turnidge formula [18]. When increasing
the dosage frequency from 4 times to 6 times a day all pa-
tients with bacterial MIC ≤ 4 reach the efficacy target and
95% (54/57) of the patients with bacterial MIC ≤ 8
(Figure 4).
Microbiological analysis
Sixteen out of twenty one abdominal fluid cultures became
positive, 8/10 wound cultures, 7/16 blood cultures, 4/5Figure 1 The measured concentrations of amoxicillin plotted againsturine cultures and 1/2 sputum cultures became positive.
Of three patients no cultures were taken. In total thirty-
six of the 57 patients (63%) had a positive culture. Of
the positive cultures, 30 (83%) were Enterobacteriaceae;
E. coli (n = 21), Klebsiella spp. (n = 6), Enterobacter spp.
(n = 2) and Proteus spp. (n = 1). In three patients two
bacteria were isolated. Of the Gram positive cultures, 6
were Enterococcus spp, 3 Staphylococcus aureus and 1
coagulase negative staphylococcus. Forty MIC values
were available in 36 patients. Of the isolated Enterobac-
tericeae 17/30 (57%) of had a MIC ≤ 4 mg/L, 4/30 (13%)
had a MIC = 8 mg/L and 9/30 (30%) had a MIC ≥
16 mg/L. Of the isolated Gram positive bacteria 8/10
(80%) of had a MIC ≤ 1 mg/L and 2/10 (20%) had a
MIC ≥ 4 mg/L. Clinical cure was reached in 46 patients,
8 patients switched antibiotic therapy and in 3 patients
cure was not reached (of which two died). No significant
associations were found between 40%T >MIC and defe-
verescence, CRP decrease or increase, admission days
and clinical outcome (data not shown).the time after amoxicillin administration.
Figure 2 Correlation between amoxicillin actual measured concentration and estimated with maximum a posteriori Bayesian fitting
(MW/Pharm 3.60, Mediware, the Netherlands).
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In this study, we demonstrate that the efficacy target of
40%T >MIC for amoxicillin/clavulanic acid was reached
in 93% of the patients tested when the MIC was 4 mg/L
and only in 65% of the patients tested when the MIC
was 8 mg/L. In the EUCAST and CLSI criteria Entero-
bacteriaceae are considered to be susceptible for amoxi-
cillin/clavulanic acid with bacterial MIC ≤ 8 mg/L [11].
High bacterial MICs for amoxicillin/clavulanic acid are
an increasing problem in the Netherlands and in EuropeFigure 3 The percentage of patients that reach the 40%T >MIC for di[19,20]. To prevent treatment failure for individual pa-
tients and to prevent development of antibiotic resist-
ance on population level, increasing the standard dose of
amoxicillin/clavulanic acid seems warranted. Dosing
simulation showed that increasing the standard dose of
amoxicillin/clavulanic acid to 6 times a day 1000/200 mg
increased the number of patients reaching 40%T >MIC
to 100% for bacterial MIC ≤ 4 and to 95% with bacterial
MIC ≤ 8. Continuous iv dosing is an alternative for fre-
quent dosing of time dependent β-lactam antibiotics.fferent age categories at different MICs.
Table 3 Univariate Pearson correlation coefficients
between amoxicillin/clavulanic acid, CLam/W and







40%T >MIC −0.424 0.025
CLam/W, amoxicillin/clavulanic acid clearance corrected for bodyweight.
V/W, amoxicillin/clavulanic acid volume of distribution corrected
for bodyweight.
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ous iv dosing, because of the instability of amoxicillin at
room temperature. Therefore, we suggest increasing the
dose of amoxicillin/clavulanic acid to 6 times a day in pa-
tients with severe Enterobacteriaceae sepsis or intra-
abdominal infection.
In general amoxicillin/clavulanic acid is well tolerated.
The most frequent adverse drug events are diarrhoea,
nausea and vomiting. However, amoxicillin/clavulanic
acid is also associated with liver injury, which is esti-
mated to occur from 1 to 1.7 per 10.000 users [21,22].
Clavulanic acid seems to be responsible for the adverse
drug reaction, since amoxicillin alone is rarely associated
with liver injury and causes less gastrointestinal prob-
lems than the combination preparation [23-25]. In vitro
pharmacodynamic studies demonstrate that low dose of
clavulanic acid suffice and the β-lactamase inhibition of
clavulanic acid lasts for 8–12 hours [26,27]. Therefore,
increasing the standard dose of amoxicillin/clavulanic















































Figure 4 Calculated percentage of patients with 40%T >MIC at differtwice daily 1000 mg iv may be a safe and effective
alternative.
CLam/W is correlated with CLcr and the amoxicillin
dose is adjusted with to the CLcr. However, other covariates
also influence the CLam/W. CLam/W was significantly
correlated with age. However, age and creatinine were not
correlated to each other, meaning that elderly patients can
have both a normal creatinine and a decreased CLam/W.
Therefore, the correlation of age with CLam/W seems in-
dependent of the creatinine. Furthermore, the 4 patients
that did not reach the efficacy target with bacterial MIC = 4
were all young patients with excellent clearance. Our mea-
sured attainment results are lower than those calculated at-
tainment results in the EUCAST rationale document, in
which Monte Carlo simulations were used to calculate the
target attainment rates (40%T >MIC) of different dosing
regimens (from 500 mg 3 times a day to 2 g 4 times a day)
for different bacterial MICs (0.5-32 mg/L) [11]. The target
attainment in the EUCAST rationale document for the
standard dose (1000/200 mg 4 times a day) is 100% at bac-
terial MIC ≤ 4 and 75% with bacterial MIC ≤ 8 mg/L [11].
In our real life blood level determination study, these per-
centages were 93% and 65%, respectively. This difference
may be explained by the larger interindividual variability of
our population and in particular by a group of younger pa-
tients with normal renal clearance (CLcr > 60 mL/min).
Remarkably, in the EUCAST rationale document, the inter-
individual variation is extremely small; t½ is 1.1 (±0.1) h,
versus t½ is 1.5 (±0.6) h in our study. The higher t½ in our
study may be due to the high mean age of our population.
No significant associations have been found between the
target 40%T >MIC and clinical outcome. As expected,
our study population was too small and too heteroge-





ent MICs for increasing amoxicillin dosages.
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study, ceftazidim has been shown to be maximally effect-
ive when 40%T >MIC was reached for concentrations
four times the MIC or higher [28]. In our study, the target
of 40%T > 4 ×MIC was only reached in 100% for low
MICs (≤1 mg/L), but never for bacterial MICs of 4 and
8 mg/L. Our study was not designed to isolate a large
number of bacterial MICs and therefore only a limited
number of clinical bacterial MICs were available in our
study. Taken together a large clinical PK/PD study of
amoxicillin/clavulanic acid is needed with microbiological
and clinical cure endpoints to establish the association be-
tween clinical endpoints and the efficacy target 40%T >
MIC.
Conclusions
The current standard dose of amoxicillin/clavulanic acid 4
times a day 1000/200 mg iv is too low to reach the 40%T >
MIC for bacterial MIC of 8 mg/L in a high percentage of
patients. To prevent treatment failure for individual pa-
tients and to prevent development of antibiotic resistance
on population level, we suggest increasing the standard
dose of amoxicillin/clavulanic acid to 6 times a day in pa-
tients with an Enterobacteriaceae sepsis or intra-abdominal
infection.
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